Ovary Syndrome Articles & Analysis
2 news found
In March 2020, the CE Mark label for Revita DMR was expanded from its original label for patients with poorly controlled type 2 diabetes on oral medications to include insulin withdrawal for patients with T2D, improvements in NAFLD/NASH in patients with T2D, and improvements in insulin sensitivity in patients with polycystic ovary syndrome (PCOS). In the United ...
AblaCare, a company developing a minimally invasive approach for the treatment of polycystic ovary syndrome (PCOS) related infertility, was the second-place winner of the audience vote. ...